Supportive care—rehydration with oral or intravenous fluids—and treatment of specific symptoms improves survival. A range of potential treatments including blood products, immune therapies and drug therapies are currently being evaluated.
During the 2018–2020 Ebola virus disease (EVD) outbreak caused by Zaire ebolavirus in the Democratic Republic of the Congo, the first-ever multi-drug randomized control trial was conducted to evaluate the effectiveness and safety of drugs used in the treatment of EVD patients under an ethical framework developed in consultation with experts in the field and the DRC.
Two monoclonal antibodies (Inmazeb and Ebanga) were approved for the treatment of Zaire ebolavirus infection in adults and children by the US Food and Drug Administration in late 2020.